Sirona Biochem (Seite 1396)

[Wilhelm_Tell]

Antwort auf Beitrag Nr.: 61.696.051 von Effenberg65 am 15.10.19 15:45:30

Irgendwann knallt es – evt. auch ohne News. Die Story sollte immer bekannter werden – auch bei Leuten mit grossen Hosentaschen.

Diese zwei Punkt der News gefallen mir aussergewöhnlich gut:

Die Datenanalyse zeigt außerdem eine Trendentwicklung auf, nach der die Fähigkeit von TFC-1067, Flecken mit der umgebenden Haut zu verblenden, im Laufe der Zeit - auch über die Studiendauer von 12 Wochen hinaus - weiter zunehmen könnte.
Das Führungsteam von Rodan + Fields wird seinen Plan hinsichtlich der Einbindung von TFC-1067 in die Kollektion seiner lebensverändernden Hautpflegeprodukte darlegen.

[Effenberg65]

Ich bin mal gespannt WANN es gen Norden knallt ..😉Es wird ja auch immer die Zukunft gehandelt und irgendwann ist es zu spät einzusteigen 🤔🚄🚄🚄👏

[Wilhelm_Tell]

Antwort auf Beitrag Nr.: 61.695.175 von Hydro_11 am 15.10.19 14:13:47

her vision in anti-aging therapies

Auch anti-aging therapies wird offizell ein Rand Thema sein... und ich bin mir sicher hinter geschlossen Türen wird das Intresse auch hier gross sein.


The event will be held at the US Block of the Cosmetic 360 conference in Paris on October 16th starting at 12:00 PM. Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will introduce TFChem, the wholly owned French subsidiary of Sirona Biochem, which has created breakthrough skin care solutions using platform-based technology. Dr. Deliencourt-Godefroy will highlight her innovative dark spot treatment, TFC-1067, as well as touch on her vision in anti-aging therapies.

[Hydro_11]

Sirona Biochem: Agreement Signing Ceremony with Rodan + Fields at Cosmetic 360 Conference in Paris

Vancouver, British Columbia – October 15, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it will have a signing ceremony of its TFC-1067 License and Supply agreement with Rodan + Fields, LLC (“Rodan + Fields”). Rodan + Fields, the leading skin care brand in the United States, is preparing to incorporate novel ingredient TFC-1067 into their product lines. Backed by extensive scientific research, TFC-1067 is clinically proven to be safe and effective at reducing the visibility of dark spots, brightening and evening skin tone. 
The event will be held at the US Block of the Cosmetic 360 conference in Paris on October 16th starting at 12:00 PM. Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will introduce TFChem, the wholly owned French subsidiary of Sirona Biochem, which has created breakthrough skin care solutions using platform-based technology. Dr. Deliencourt-Godefroy will highlight her innovative dark spot treatment, TFC-1067, as well as touch on her vision in anti-aging therapies.
In attendance will be members of government who have been of tremendous support in the growth of TFChem as well as local media.
Rodan + Fields executive team will present their plan to use TFC-1067 within their collection of life-changing skin care products. 
Team members from TFChem and its parent company Sirona Biochem will be available throughout the conference at booth N1. The team will have additional data analysis available from the clinical trial previously reported on April 10th, 2019. The data analysis more clearly demonstrates the established consumer benefit of TFC-1067. TFC-1067 achieved the unique goal of statistically significant selective decreased in melanin scores in dyschromic skin compared to normal skin.  
Most consumers desire lightening of dark spots to blend into surrounding skin. TFC-1067 achieved this goal, while the 2% hydroquinone comparator did not. The value of this benefit to the consumer cannot be underestimated. Further data analysis also showed a trend that TFC-1067’s ability to blend spots into the surrounding skin would increase over time beyond the 12 weeks of the trial. The Company is currently working on a submission of these results for a peer-reviewed scientific journal. 
The commercial value of TFC-1067 has been confirmed by the agreement with Rodan+ Fields. Sirona’s management and TFChem’s scientific team are exploring additional partnering opportunities while continuing to explore ways to further demonstrate and unlock the value of TFC-1067 for the consumer. An update regarding these plans will be released as they are finalized.
About Rodan + Fields
Founded by Stanford-trained dermatologists Dr. Katie Rodan and Dr. Kathy Fields, Rodan + Fields was launched in 2002 with the mission of giving consumers the best skin of their lives. The brand is a result of the Doctors’ belief that healthy skin empowers people to feel confident. Born in the digital era and designed to directly reach consumers where they live and shop via mobile and social networks, Rodan + Fields is disrupting the industry with its regimen-based skincare and powerful Independent Consultant community.

For more information, please visit www.rodanandfields.com
About TFChem 
TFChem are experts in the field of carbohydrate and fluorine chemistry. The company has developed a unique know-how which combines these two technical domains in order to create new therapeutic candidates based on original carbohydrate mimics. 
TFChem has become a leader in the area of fluorinated glycosides and their application as new, more potent and safer therapies in both pharmaceuticals and skincare. TFChem brings a unique solution to the severe drawbacks (stability and bioavailability) usually associated with carbohydrate-based compounds and thus allows the full exploitation of their therapeutic potential and the development of new technology.
TFChem is the recipient of multiple French national scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com/about-tfchem/about-tfchem-2/ 
About Cosmetic 360
Cosmetic 360 is an innovative-centered trade fair for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including raw materials, formulation, packaging, testing and analysis, finished products, and distribution. This year Cosmetic 360 has chosen to spotlight the United States, a leader in the beauty sector. More information on the conference can be found at www.cosmetic-360.com/en.

For more information regarding this press release, please contact:

Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: [phone]
Email: [e-mail]  
Corporate Enquiries:
Dr. Howard Verrico
CEO, Chairman of the Board
Sirona Biochem Corp.
Phone: [phone]
Email: [e-mail]

[grounding]

Antwort auf Beitrag Nr.: 61.687.519 von Geheimnisvoller am 14.10.19 13:45:59

Zitat von Geheimnisvoller: Eine News am Mi. vor oder auf dem Kosmetic-Event wäre famos

Ankündigung war:

"Sirona Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France"

.... also werden wir neue Ergebnisse hören, die den Kurs evtl. ankurbeln.

da bin ich mir ebenfalls ziemlich sicher 😎👍🏻

[freixenetter]

Antwort auf Beitrag Nr.: 61.689.829 von Wilhelm_Tell am 14.10.19 20:13:02

Ich denke nach der Ankündigung vom 25.09.2019 braucht man sich da keine Hoffnungen machen. Eine ‚Vermarktung‘ des Abschlusses 1067 wird aber auch nicht ungehört bleiben

[Hrubesch09]

Antwort auf Beitrag Nr.: 61.689.517 von Billi11 am 14.10.19 19:30:41

Ich bin für Vagina

Creme, Phase 1. Wee will see, Depot schau in 2022, Fragen?

[Wilhelm_Tell]

Antwort auf Beitrag Nr.: 61.689.517 von Billi11 am 14.10.19 19:30:41

Ja, LIP01 wird sicher ein grosses Thema sein.
Vielleicht hören von dieser Seite etwas.

[Billi11]

Antwort auf Beitrag Nr.: 61.689.262 von new_investor am 14.10.19 18:43:08

Denke da eher an Howie' Überraschung, Akne oder anti aging ??

[new_investor]

Antwort auf Beitrag Nr.: 61.689.376 von papermani am 14.10.19 19:05:21

TFChem = 100% Tochter von Sirona...wo ist das Problem?

Schau mer mal😎🤠